Last reviewed · How we verify
Multi-dose Quadrivalent Influenza Vaccine
This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.
This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Multi-dose Quadrivalent Influenza Vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent influenza vaccine contains inactivated viral antigens from four influenza strains (two A subtypes and two B lineages). When administered, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that recognize and neutralize circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (PHASE1, PHASE2)
- Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India (PHASE4)
- A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (PHASE4)
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (PHASE3)
- Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: